Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 2/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223473 | 0.85 | KCNH2 (0.34) | LMNATSHRCHRNA7NPC1KCNH2 | |
| SCHEMBL5040313 | 0.83 | DCUN1D1 (0.38) | UBE2MDCUN1D1CHRNA7KCNH2HTR2A | |
| SCHEMBL2767755 | 0.82 | KDM4E (0.37) | DCUN1D1CHRNA7KCNH2 | |
| Water SCHEMBL3517045 | 0.81 | KDM4E (0.37) | DCUN1D1KCNH2 | |
| SCHEMBL2799450 | 0.81 | UBE2M (0.58) | UBE2MDCUN1D1LMNATSHR | |
| SCHEMBL3515920 | 0.81 | CHRM2 (0.53) | UBE2MDCUN1D1LMNA | |
| SCHEMBL12081174 | 0.80 | HTR2A (0.35) | UBE2MDCUN1D1KCNH2HTR2A | |
| SCHEMBL2799356 | 0.79 | UBE2M (0.34) | UBE2MDCUN1D1LMNATSHRCHRNA7 | |
| SCHEMBL4140059 | 0.78 | ALDH1A1 (0.36) | DCUN1D1NPC1KCNH2 | |
| SCHEMBL11999874 | 0.77 | HSD11B1 (0.38) | UBE2MDCUN1D1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | UBE2M 2433/4885DCUN1D1 1317/4885LMNA 4185/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | UBE2M 286/4885DCUN1D1 768/4885LMNA 1679/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | UBE2M 3241/4885DCUN1D1 2601/4885LMNA 1811/4885 |
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NRDC, NCL, NPM1 | UBE2M 294/4885DCUN1D1 2004/4885LMNA 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.